Next Generation Breakthroughs For Breast Cancer Patients

Christine was diagnosed with breast cancer three months before her wedding date. For patients like Christine, and the 2.3 million women diagnosed with breast cancer globally each year, researchers at Pfizer are leveraging in-depth expertise and cutting-edge science to drive the next generation of breakthroughs. Learn more about our breast cancer development programs, including our novel CDK4 and KAT6 inhibitors, which are being designed to disrupt the growth of breast cancer cells and overcome resistance challenges with current therapies. The KAT6 and CDK4 inhibitor programs are investigational, and safety and efficacy have not yet been established.